콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

SML1899

Sigma-Aldrich

SR144528

≥98% (HPLC)

동의어(들):

5-(4-Chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide, SR-144528

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C29H34ClN3O
CAS Number:
Molecular Weight:
476.05
MDL number:
UNSPSC 코드:
12352200
NACRES:
NA.77

Quality Level

분석

≥98% (HPLC)

형태

powder

색상

white to beige

solubility

DMSO: 10 mg/mL, clear

저장 온도

−20°C

SMILES string

C[C@]12[C@H](NC(C3=NN(CC4=CC=C(C)C=C4)C(C5=CC=C(Cl)C(C)=C5)=C3)=O)C(C)(C)[C@@H](C2)CC1

InChI

1S/C29H34ClN3O/c1-18-6-8-20(9-7-18)17-33-25(21-10-11-23(30)19(2)14-21)15-24(32-33)26(34)31-27-28(3,4)22-12-13-29(27,5)16-22/h6-11,14-15,22,27H,12-13,16-17H2,1-5H3,(H,31,34)/t22-,27-,29+/m1/s1

InChI key

SUGVYNSRNKFXQM-XRHWURSXSA-N

애플리케이션

SR144528 has been used as a cannabinoid CB2 receptor antagonist:
  • to study its blocking effect on the anti-dyskinetic functionality of HU-308
  • to study its effects on spontaneous excitatory postsynaptic currents (sEPSCs) from the globus pallidus neurons
  • to analyze its effect on the gastric emptying in rats

생화학적/생리학적 작용

SR144528 is a potent and highly selective cannabinoid CB2 receptor inverse agonist. SR144528 exhibited a Ki of 0.6 nM at CB2 compared to 400 nM at the related CB1 receptor.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

I Freiman et al.
Neuroscience, 133(1), 305-313 (2005-05-17)
The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB1 cannabinoid receptors. The hypothesis of the present work was that CB1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that
Qiang Tan et al.
Brain research, 1654(Pt A), 24-33 (2016-10-23)
Fibrosis in ventricular system has a role in hydrocephalus following intraventricular hemorrhage (IVH). The cannabinoid receptor 2 (CB2) has been reported to participate in alleviating the fibrosis process of many diseases. However, its role in fibrosis after IVH was unclear
M Rinaldi-Carmona et al.
The Journal of pharmacology and experimental therapeutics, 284(2), 644-650 (1998-03-07)
Based on both binding and functional data, this study introduces SR 144528 as the first, highly potent, selective and orally active antagonist for the CB2 receptor. This compound which displays subnanomolar affinity (Ki = 0.6 nM) for both the rat
A A Izzo et al.
Naunyn-Schmiedeberg's archives of pharmacology, 360(2), 221-223 (1999-09-24)
We have studied the effect of WIN 55,212-2 (a psychoactive cannabinoid agonist), cannabinol (a nonpsychoactive cannabinoid agonist), SR141716A, a cannabinoid CB1 antagonist, and SR144528, a cannabinoid CB2 antagonist, on gastric emptying in the rat. WIN 55,212-2 (0.1-5 mg/kg, i.p.) and
Peggy Rentsch et al.
Neurobiology of disease, 134, 104646-104646 (2019-11-02)
L-dopa induced dyskinesia (LID) is a debilitating side-effect of the primary treatment used in Parkinson's disease (PD), l-dopa. Here we investigate the effect of HU-308, a cannabinoid CB2 receptor agonist, on LIDs. Utilizing a mouse model of PD and LIDs

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.